🫁 Lung/Head and Neck — 2026-W35

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Randomized phase 2 trial in previously untreated recurrent/metastatic HNSCC testing addition of a novel STAT3-targeting antisense oligonucleotide (danvatirsen) to pembrolizumab, published in Clinical Cancer Research. The combination failed to improve response rates over pembrolizumab alone and increased toxicity, arguing against pursuing this novel target in this setting.

Phase 3 randomized trial (KEYNOTE-671) reporting 5-year follow-up of perioperative pembrolizumab plus chemotherapy in resectable NSCLC, published in Annals of Oncology. Confirms durable event-free and overall survival benefit without quality-of-life detriment, reinforcing this regimen as standard of care in early-stage NSCLC.

Updated NCCN Clinical Practice Guidelines (Version 3.2026) for pleural mesothelioma. Provides the current consensus-based standard for evaluation and treatment that oncologists should follow.

ASCO Living Guideline update on systemic therapy for stage IV NSCLC with driver alterations, published in JCO. Provides current, continuously-updated society recommendations that directly guide first-line and subsequent treatment selection in oncogene-driven NSCLC.

Translational biomarker study in oncogene-driven NSCLC patients progressing on EGFR/ALK/MET/ROS1/RET inhibitors, published in Annals of Oncology, using tissue/liquid biopsies and patient-derived models to characterize RAS-mediated resistance. Identifies RAS alterations as a resistance mechanism varying by inhibitor type, supporting rationale for RAS-directed therapy to overcome off-target resistance.

Phase 1 trial of the EGFR-targeting antibody-drug conjugate SYS6010 in previously treated advanced NSCLC, published in Cancer Cell, showing manageable safety and encouraging objective responses and survival across EGFR-mutant and wild-type subgroups, supporting further development in this refractory population.

Pan-cancer genomic analysis (Clin Cancer Res, elite/Q1) characterizing SMARCA4 alteration classes across tumor types, showing that patients with monoallelic class 2 SMARCA4 alterations and preserved BRG1 benefited from a BRM-degrader phase 1 trial. Suggests a biomarker-defined strategy for selecting patients for BRM-degrader therapy across SMARCA4-altered cancers.

Secondary pathologic analysis of the JCOG0802/WJOG4607L phase 3 surgical trial in stage IA NSCLC, published in J Thorac Oncol, examining tumor spread through air spaces (STAS) as a prognostic factor after segmentectomy versus lobectomy. Informs prognostic stratification and surgical decision-making in early-stage lung cancer, with potential implications for identifying patients who may need closer follow-up or adjuvant consideration.

Single-arm phase 2 trial with multi-omics analysis in J Immunother Cancer testing durvalumab plus olaparib maintenance after chemoimmunotherapy in previously untreated extensive-stage small-cell lung cancer. Shows encouraging efficacy and identifies a DNA hypomethylation subgroup linked to better outcomes, suggesting a potential biomarker-selected maintenance strategy pending randomized confirmation.

Narrative review in Lung Cancer covering the biology, detection, and risk stratification of incidental pulmonary nodules, including the emerging role of targeted therapy for oncogene-driven early lesions. Offers a state-of-the-art overview relevant to how oncologists approach nodule workup and early targeted intervention, though it is not primary trial data.

Multicentre retrospective real-world study in Lung Cancer comparing immunotherapy outcomes in KRAS G12C versus non-G12C mutant NSCLC. Finds G12C mutation associated with better overall survival on ICI, providing prognostic nuance but not altering current treatment selection.

Multicenter retrospective cohort study in resected limited-stage small-cell lung cancer, published in Lung Cancer, showing that pathological complete response after neoadjuvant immunochemotherapy (but not chemotherapy alone) correlates with better event-free survival, suggesting pCR's prognostic value may depend on treatment type.

Single-arm phase 2 trial in Chinese patients with BRAFV600E-mutated metastatic NSCLC, published in Lung Cancer. Shows encorafenib plus binimetinib produces durable responses, supporting this targeted combination as an option in this molecular subgroup.

Single-center retrospective cohort in unresectable stage III NSCLC comparing induction versus consolidation chemoimmunotherapy with definitive radiotherapy, published in Lung Cancer. Suggests induction timing may improve progression-free survival and downstaging without added toxicity, informing sequencing of immunotherapy with chemoradiation.

Translational study characterizing spatial tumor immune microenvironment differences across EGFR mutation subtypes in early-stage lung adenocarcinoma, published in Lung Cancer. Findings are hypothesis-generating regarding potential perioperative treatment selection but require prospective validation before informing clinical decisions.

Multicenter retrospective analysis of transformed small-cell lung cancer arising from EGFR-mutant NSCLC, published in Lung Cancer, characterizing genomic predictors and comparing post-transformation treatment regimens. Suggests taxane-based later-line therapy may outperform other regimens, offering practical guidance for this resistance pattern.